TherapeuticsMD, Inc. operates as a women’s health care product company in the United States.
High growth potential and slightly overvalued.
Share Price & News
How has TherapeuticsMD's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TXMD's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: TXMD underperformed the US Pharmaceuticals industry which returned 6.1% over the past year.
Return vs Market: TXMD underperformed the US Market which returned 19.3% over the past year.
Price Volatility Vs. Market
How volatile is TherapeuticsMD's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StBefore You Buy TherapeuticsMD, Inc. (NASDAQ:TXMD), Consider Its Volatility
1 month ago | Simply Wall StHow Much Are TherapeuticsMD, Inc. (NASDAQ:TXMD) Insiders Spending On Buying Shares?
2 months ago | Simply Wall StHow Much Of TherapeuticsMD, Inc. (NASDAQ:TXMD) Do Insiders Own?
Is TherapeuticsMD undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TXMD ($2.15) is trading below our estimate of fair value ($21.34)
Significantly Below Fair Value: TXMD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TXMD is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: TXMD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TXMD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TXMD has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.
How is TherapeuticsMD forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TXMD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: TXMD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TXMD's is expected to become profitable in the next 3 years.
Revenue vs Market: TXMD's revenue (42.2% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: TXMD's revenue (42.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TXMD's Return on Equity is forecast to be high in 3 years time
How has TherapeuticsMD performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TXMD is currently unprofitable.
Growing Profit Margin: TXMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TXMD is unprofitable, and losses have increased over the past 5 years at a rate of -18.8% per year.
Accelerating Growth: Unable to compare TXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: TXMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is TherapeuticsMD's financial position?
Financial Position Analysis
Short Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: TXMD has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: TXMD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: TXMD has a low level of unsold assets or inventory.
Debt Coverage by Assets: TXMD has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TXMD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TXMD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is TherapeuticsMD's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate TXMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TXMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TXMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TXMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TXMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rob Finizio (48yo)
Mr. Robert G. Finizio, also known as Rob, is the Co-Founder of TherapeuticsMD, Inc. and has been its Chief Executive Officer since October 4, 2011. Mr. Finizio serves as Director of ZyVersa Therapeutics, I ...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD1.66M).
Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.
|Co-Founder||8.3yrs||no data||7.5% $43.7m|
|President||8.3yrs||no data||2.05% $12.0m|
|CFO & Treasurer||8.3yrs||no data||no data|
|Executive VP and Chief Strategy & Performance Officer||8.3yrs||no data||no data|
|Vice President of Finance||6.8yrs||no data||no data|
|Vice President of Commercial Development & Operations||0yrs||no data||no data|
|Chief Scientific Officer and Head of Regulatory Department||6.2yrs||no data||no data|
|Chief Information Officer||1.9yrs||no data||no data|
|Vice President of Investor Relations||2.1yrs||no data||no data|
Experienced Management: TXMD's management team is seasoned and experienced (7.6 years average tenure).
|Co-Founder||8.3yrs||no data||7.5% $43.7m|
|President||8.3yrs||no data||2.05% $12.0m|
|Independent Director||4.9yrs||US$256.29k||0.034% $201.0k|
|Independent Director||4.9yrs||US$260.79k||0.0037% $21.5k|
|Independent Chairman of the Board||7.8yrs||US$378.31k||0.26% $1.5m|
|Independent Director||8yrs||US$272.54k||0.024% $141.9k|
|Independent Director||8yrs||US$252.54k||0.22% $1.3m|
|Independent Director||6.8yrs||US$245.04k||0.0018% $10.7k|
|Independent Director||8yrs||US$275.04k||0.0037% $21.5k|
Experienced Board: TXMD's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.
TherapeuticsMD, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: TherapeuticsMD, Inc.
- Ticker: TXMD
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$583.031m
- Shares outstanding: 271.18m
- Website: https://www.therapeuticsmd.com
Number of Employees
- TherapeuticsMD, Inc.
- 951 Yamato Road
- Suite 220
- Boca Raton
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TXMD||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2011|
|29T||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2011|
TherapeuticsMD, Inc. operates as a women’s health care product company in the United States. The company’s hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/21 01:11|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.